Report
MaaT Pharma MaaT013 PIP approval clears path for MAA submission in June 2025
MaaT announced that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has approved the pediatric investigation plan (PIP) for MaaT013 for the treatment of acute Graft-versus-Host Disease (aGvHD). The approval of the pediatric investigation plan (PIP) for MaaT013 in aGvHD is a positive step for the company as an approved PIP is a prerequisite for filing a marketing authorization application (MAA). As such, MaaT is on track to submit the MAA for MaaT013 in Europe in June 2025, which means the product could be approved by late 2026. We reiterate our € 18 TP and BUY rating.
Underlying
MAAT PHARMA SA
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.